CLL | Tumor

CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.

Initiating Therapy in CLL

February 1st 2021

Options for Managing Refractory CLL

February 1st 2021

Predicting Response to Therapy in CLL

February 1st 2021

CLL: A Cancer of the Blood

February 1st 2021

Patient Perspectives on the CLL Treatment Paradigm

February 1st 2021

A Diagnosis of Chronic Lymphocytic Leukemia With ITP

February 1st 2021

Significance of Watch-and-Wait Approach in CLL

February 1st 2021

Why It's an Exciting Time for Patients With CLL

January 31st 2021

For Younger Patients, CAR T-Cell Therapy Could Play a Role in CLL Treatment

January 18th 2021

In an interview, Dr. Matthew Davids of the Dana-Farber Cancer Institute discusses the future of CAR T-Cell therapy in the treatment of younger patients with chronic lymphocytic leukemia.

Areas Patients with CLL Can Focus On to Maintain Their Health Beyond Treatment

January 15th 2021

In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute discussed why it’s important for patients with CLL, regardless of their treatment plans, to keep up on vaccinations and maintain a regular cancer screening schedule.

Adding Copiktra to Standard of Care Chemotherapy Combination in CLL Could Improve Outcomes, But Not Without Toxicities

January 14th 2021

In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute in Boston discussed how the addition of Copiktra to a three-drug chemotherapy combination improved outcomes in patients with CLL, with more than half achieving complete remission.

The Treatment Journey of a Patient with CLL

December 31st 2020

In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with chronic lymphocytic leukemia, about his diagnosis and treatment journey.

Early Use of Fixed-Duration Venclexta-Rituxan Combo in Patients with Relapsed/Refractory CLL Effective, And Does Not Compromise Subsequent Therapy Response in Patients Who Need Retreatment

December 14th 2020

More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the therapy.

Venclexta Added to Novel Combination Therapy Elicits High Responses in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

December 14th 2020

Among 27 patients with relapsed/refractory chronic lymphocytic leukemia patients who completed all 12 cycles of the triplet therapy, 100% of patients had a complete or partial response to the treatment—with 41% achieving a complete response.

Novel Combination Therapy Contributes to Additional Progression-Free Survival Benefit Compared With Chemoimmunotherapy in Patients with CLL

December 9th 2020

The combination of ublituximab and umbralisib, two novel compounds, was able to safely prolong progression-free survival with low rates of toxicities in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy regardless of prior treatment.

Calquence Use Associated With Limited Heart Toxicities in Patients With Chronic Lymphocytic Leukemia

December 8th 2020

At a median follow-up of 25.9 months, 17% of the patient population who received Calquence monotherapy experienced a cardiac toxicity of any severity, which led to treatment discontinuation in only seven patients.

Investigational CAR-T Cell Therapy Lisocabtagene Maraleucel Shows Durable Responses in Patients with Relapsed/Refractory CLL/SLL

December 8th 2020

The early study of the investigational CAR-T cell therapy lisocabtagene maraleucel shows how patients with relapsed/refractory CLL/SLL may have a viable new treatment option.

Imbruvica-Based Treatment Elicited Long-Term Survival Benefits in Subset of Patients With CLL Who Historically Have Poor Outcomes

December 7th 2020

Imbruvica treatment in patients with chronic lymphocytic leukemia whose disease expressed a certain mutation elicited sustained efficacy over a median follow-up of four years, according to data from a long-term analysis.

Traditional Definition of ‘High-Risk’ in Patients With CLL and SLL Outdated, Needs to be Revisited

December 7th 2020

In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.

Venclexta-Rituxan Combo Continues to Show Survival Benefit Through 5 Years in Relapsed/Refractory CLL

December 5th 2020

Compared with patients assigned bendamustine with Rituxan, those assigned Venclexta with Rituxan maintained an overall survival benefit, with a five-year OS estimate of 82.1% for the Venclexta with Rituxan group vs. 62.2% for the bendamustine with Rituxan group.

Data Support Fixed-Treatment Duration of Imbruvica/Venclexta Combo Could Lead to Treatment Discontinuation in Certain Patients With CLL/SLL

December 5th 2020

Data suggest that patients with CLL/SLL who achieve confirmed undetectable minimal residual disease following 12 cycles of Imbruvica combined with Venclexta could possibly discontinue and reasonably remain off treatment.

When and How CLL, SLL Should Be Treated

November 5th 2020

New treatment options are outperforming the “old-fashioned” chemotherapy regimens for patients with CLL and SLL, according to Dr. Locke J. Bryan.

Progression-Free Survival, Overall Survival Sustained at Four Years with Venclexta Plus Rituxan in Patients With CLL

November 4th 2020

This benefit observed with Venclexta (venetoclax) plus Rituxan (rituximab) for patients with CLL was particularly strong in patients with undetectable minimal residual disease, which may predict clinical outcome after chemoimmunotherapy.

Understanding the Pendulum Swing in CLL Research Over the Last Decade

October 15th 2020

In this episode of the “CURE Talks Cancer” podcast, we spoke with an expert from Dana-Farber Cancer Institute in Boston about the results of an early-phase clinical trial that assessed the efficacy of a combination therapy in the frontline setting in patients with CLL aged 65 years and younger, as well as a pendulum swing in research over the last decade.

Lifestyle Changes After Being Diagnosed with CLL

October 14th 2020

Advice for Patient's and Caregivers

October 14th 2020

Chronic Lymphocytic Leukemia Support Network

October 14th 2020

Achieving Minimum Residual Disease Remission

October 14th 2020

The Patient's Role in Deciding a Treatment

October 14th 2020

CD20 Monoclonal Antibody Dose Adjustment and MRD

October 14th 2020